42 reports of this reaction
1.6% of all BUPRENORPHINE AND NALOXONE reports
#15 most reported adverse reaction
CARDIO RESPIRATORY ARREST is the #15 most commonly reported adverse reaction for BUPRENORPHINE AND NALOXONE, manufactured by Amneal Pharmaceuticals LLC. There are 42 FDA adverse event reports linking BUPRENORPHINE AND NALOXONE to CARDIO RESPIRATORY ARREST. This represents approximately 1.6% of all 2,589 adverse event reports for this drug.
Patients taking BUPRENORPHINE AND NALOXONE who experience cardio respiratory arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIO RESPIRATORY ARREST is a less commonly reported adverse event for BUPRENORPHINE AND NALOXONE, but still significant enough to appear in the safety profile.
In addition to cardio respiratory arrest, the following adverse reactions have been reported for BUPRENORPHINE AND NALOXONE:
The following drugs have also been linked to cardio respiratory arrest in FDA adverse event reports:
CARDIO RESPIRATORY ARREST has been reported as an adverse event in 42 FDA reports for BUPRENORPHINE AND NALOXONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIO RESPIRATORY ARREST accounts for approximately 1.6% of all adverse event reports for BUPRENORPHINE AND NALOXONE, making it a notable side effect.
If you experience cardio respiratory arrest while taking BUPRENORPHINE AND NALOXONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.